Tom Powles, Professor of Urology Cancer at the University of London and the Director of Barts Cancer Centre, shared a post on X:
“Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)).
The shorter period of EV is the major difference in trial designs. Details of efficacy and toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage.”
Other articles featuring Tom Powles on OncoDaily.